Effects of 5,8-dideazaisofolic acid (IAHQ) on human tumor cells in culture and on normal and tumor-bearing hamsters.
The quinazoline analog of folic acid, 5,8-dideazaisofolic acid (IAHQ), was tested for its effects on the growth of human tumor cells in vitro and in vivo. Of 23 human tumor cell lines tested in vitro, 7 were inhibited by IAHQ (ED50, 5 X 10(-6) to 5 X 10(-7) M). For in vivo studies, human osteosarcoma (OS) cells from the IAHQ-sensitive line TE-85 were implanted intraperitoneally in newborn hamsters: in the group treated with IAHQ, only 30% of the animals developed OS, compared with 100% of those not treated with IAHQ. The effects of IAHQ injections on mitogenic responses and natural killer activity of lymphocytes from normal 3-month-old hamsters were also examined.
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D006224:Cricetinae; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004351:Drug Resistance; D005260:Female; D005493:Folic Acid Antagonists / Q000494:pharmacology*; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008727:Methotrexate / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy*; D012516:Osteosarcoma / Q000188:drug therapy; D011247:Pregnancy; D011799:Quinazolines / Q000627:therapeutic use*; D012513:Sarcoma, Experimental / Q000188:drug therapy
D005493:Folic Acid Antagonists; D011799:Quinazolines; C035530:5,8-dideazaisofolic acid; D008727:Methotrexate